Nil Urganci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nil Urganci has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Jinru Shia
Memorial Sloan Kettering Cancer Center
9 shared publications - Alexander Drilon
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
8 shared publications - Andrea Cercek
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
8 shared publications - Benoit Rousseau
Memorial Sloan Kettering Cancer Center, New York, NY, USA
8 shared publications - Callahan M. Wilde
Memorial Sloan Kettering Cancer Center 1 Division of Solid Tumor Oncology, Department of Medicine New York, New York
8 shared publications - Chiara Cremolini
Department of Oncology, University Hospital of Pisa, Pisa, Italy
8 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7304
Histopathological Changes in the Uterus, Ovaries, and Fallopian Tubes Following Testosterone Therapy in Transgender Men: A Retrospective Cohort Study from a Tertiary Referral Center
Background: Gender-affirming testosterone therapy is an essential component of medical transition for transgender men. Despite its widespread use, the histopathological effects of testosterone exposure on the uterus, ovaries, and fallopian tubes remain incompletely characterized. This study aimed to characterize histopathological findings in the gynecologic organs of transgender men receiving testosterone therapy before gender-affirming hysterectomy with bilateral salpingo-oophorectomy. Methods: This retrospective cohort study included transgender men who underwent laparoscopic hysterectomy with bilateral salpingo-oophorectomy at a tertiary referral center between 2015 and 2019. Demographic characteristics, duration of testosterone therapy, operative findings, and histopathological results were reviewed. Estrogen receptor (ER) and progesterone receptor (PR) expression in uterine tissues was assessed immunohistochemically. Results: Fifty-two transgender men were included. The median age was 25.5 years (range, 19–46 years), the median body mass index was 24.8 kg/m2, and the mean duration of testosterone therapy was 16.1 ± 7.8 months. Proliferative endometrium was the predominant pattern (78.8%), followed by inactive (17.3%) and atrophic (3.8%) endometrium. Endometrial polyps were identified in 13.5% of patients. Multifollicular ovarian morphology was observed in 90.4%, and paratubal cysts in 63.5%. No premalignant or malignant lesions were detected. ER expression was positive in all endometrial samples and in 92% of myometrial specimens, while PR expression was preserved in all evaluated uterine tissues. Conclusions: In this cohort, proliferative endometrium and multifollicular ovarian morphology were common despite testosterone therapy, and uterine ER and PR expression remained detectable. The absence of premalignant or malignant lesions was reassuring within the observed exposure period; however, the retrospective design, modest sample size, absence of a control group, limited characterization of hormone exposure, and lack of longitudinal follow-up preclude conclusions regarding long-term oncologic safety or malignancy risk.
- 20 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7304
Open AccessHistopathological Changes in the Uterus, Ovaries, and Fallopian Tubes Following Testosterone Therapy in Transgender Men: A Retrospective Cohort Study from a Tertiary Referral Center
Background: Gender-affirming testosterone therapy is an essential component of medical transition for transgender men. Despite its widespread use, the histopathological effects of testosterone exposure on the uterus, ovaries, and fallopian tubes remain incompletely characterized. This study aimed to characterize histopathological findings in the gynecologic organs of transgender men receiving testosterone therapy before gender-affirming hysterectomy with bilateral salpingo-oophorectomy. Methods: This retrospective cohort study included transgender men who underwent laparoscopic hysterectomy with bilateral salpingo-oophorectomy at a tertiary referral center between 2015 and 2019. Demographic characteristics, duration of testosterone therapy, operative findings, and histopathological results were reviewed. Estrogen receptor (ER) and progesterone receptor (PR) expression in uterine tissues was assessed immunohistochemically. Results: Fifty-two transgender men were included. The median age was 25.5 years (range, 19–46 years), the median body mass index was 24.8 kg/m2, and the mean duration of testosterone therapy was 16.1 ± 7.8 months. Proliferative endometrium was the predominant pattern (78.8%), followed by inactive (17.3%) and atrophic (3.8%) endometrium. Endometrial polyps were identified in 13.5% of patients. Multifollicular ovarian morphology was observed in 90.4%, and paratubal cysts in 63.5%. No premalignant or malignant lesions were detected. ER expression was positive in all endometrial samples and in 92% of myometrial specimens, while PR expression was preserved in all evaluated uterine tissues. Conclusions: In this cohort, proliferative endometrium and multifollicular ovarian morphology were common despite testosterone therapy, and uterine ER and PR expression remained detectable. The absence of premalignant or malignant lesions was reassuring within the observed exposure period; however, the retrospective design, modest sample size, absence of a control group, limited characterization of hormone exposure, and lack of longitudinal follow-up preclude conclusions regarding long-term oncologic safety or malignancy risk.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 3: Characteristics of patients with stage IV MMRd sporadic CRC from three academic Italian medical centers.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 3: Characteristics of patients with stage IV MMRd sporadic CRC from three academic Italian medical centers.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 5: Clinical course and features of patients with stage IV MMRd sporadic CRC treated with kinase inhibitors.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 5: Clinical course and features of patients with stage IV MMRd sporadic CRC treated with kinase inhibitors.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose:Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes.Experimental Design:We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69).Results:We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade.Conclusions:Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose:Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes.Experimental Design:We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69).Results:We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade.Conclusions:Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 1: Patients with MMRd sporadic CRC defined by MAPK and fusion oncogenes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 1: Patients with MMRd sporadic CRC defined by MAPK and fusion oncogenes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figures 1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Figures with Legends.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figures 1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Figures with Legends.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 4: Clinicopathologic features of patients with stage IV disease from the main MSK cohort treated with immune checkpoint blockade.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 4: Clinicopathologic features of patients with stage IV disease from the main MSK cohort treated with immune checkpoint blockade.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 2: Patients with stage IV MMRd sporadic CRC from the main MSK cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 2: Patients with stage IV MMRd sporadic CRC from the main MSK cohort.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF11
Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose: Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes. Experimental Design: We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69). Results: We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade. Conclusions: Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF11
Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose: Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes. Experimental Design: We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69). Results: We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade. Conclusions: Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- 14 June 2025
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 28 (5) , 425-428
Primary Gastrointestinal Iatrogenic Kaposi Sarcoma: A Rare Pediatric Case Report
Kaposi sarcoma (KS) is a rare, human herpesvirus-8 (HHV-8)-associated vascular tumor that primarily affects the skin but can involve visceral organs, particularly in immunosuppressed patients. While iatrogenic KS is well-documented in adults, isolated gastrointestinal involvement in pediatric cases remains unreported. We describe a 16-year-old HIV-negative male with chronic granulomatous disease (CGD) who initially presented with inflammatory bowel disease-like symptoms and was treated with immunosuppressive therapy. Over 17 months, he developed recurrent infections, hepatosplenomegaly, and ultimately intestinal perforation, necessitating emergency colectomy. Histopathology confirmed iatrogenic KS, highlighting the need for increased awareness of this rare malignancy in immunocompromised pediatric patients and carefully balancing the risks of long-term immunosuppressive therapy.
- 14 June 2025
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 28 (5) , 425-428
Primary Gastrointestinal Iatrogenic Kaposi Sarcoma: A Rare Pediatric Case Report
Kaposi sarcoma (KS) is a rare, human herpesvirus-8 (HHV-8)-associated vascular tumor that primarily affects the skin but can involve visceral organs, particularly in immunosuppressed patients. While iatrogenic KS is well-documented in adults, isolated gastrointestinal involvement in pediatric cases remains unreported. We describe a 16-year-old HIV-negative male with chronic granulomatous disease (CGD) who initially presented with inflammatory bowel disease-like symptoms and was treated with immunosuppressive therapy. Over 17 months, he developed recurrent infections, hepatosplenomegaly, and ultimately intestinal perforation, necessitating emergency colectomy. Histopathology confirmed iatrogenic KS, highlighting the need for increased awareness of this rare malignancy in immunocompromised pediatric patients and carefully balancing the risks of long-term immunosuppressive therapy.